Madrigal Pharmaceuticals, Inc. (FRA:YDO1)
Germany
· Delayed Price · Currency is EUR 494.20
-10.60 (-2.10%)
At close: Dec 5, 2025
Madrigal Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 740.64 | 180.13 | - | - | - | - | Upgrade
|
| Cost of Revenue | 35.15 | 6.23 | - | - | - | - | Upgrade
|
| Gross Profit | 705.5 | 173.9 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 715.07 | 435.06 | 108.15 | 48.13 | 37.32 | 21.86 | Upgrade
|
| Research & Development | 297.91 | 236.72 | 272.35 | 245.44 | 205.16 | 184.81 | Upgrade
|
| Operating Expenses | 1,013 | 671.78 | 380.5 | 293.57 | 242.48 | 206.67 | Upgrade
|
| Operating Income | -307.48 | -497.88 | -380.5 | -293.57 | -242.48 | -206.67 | Upgrade
|
| Interest Expense | -17.51 | -14.67 | -12.71 | -3.96 | - | - | Upgrade
|
| Interest & Investment Income | 38.98 | 46.65 | 19.58 | 2.19 | 0.36 | 4.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.34 | - | - | - | 0.27 | 0.1 | Upgrade
|
| EBT Excluding Unusual Items | -286.35 | -465.89 | -373.63 | -295.35 | -241.85 | -202.24 | Upgrade
|
| Pretax Income | -289.13 | -465.89 | -373.63 | -295.35 | -241.85 | -202.24 | Upgrade
|
| Net Income | -289.13 | -465.89 | -373.63 | -295.35 | -241.85 | -202.24 | Upgrade
|
| Net Income to Common | -289.13 | -465.89 | -373.63 | -295.35 | -241.85 | -202.24 | Upgrade
|
| Shares Outstanding (Basic) | 22 | 21 | 19 | 17 | 17 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 21 | 19 | 17 | 17 | 15 | Upgrade
|
| Shares Change (YoY) | 6.98% | 13.83% | 9.05% | 3.64% | 7.05% | 0.34% | Upgrade
|
| EPS (Basic) | -13.04 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | Upgrade
|
| EPS (Diluted) | -13.04 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | Upgrade
|
| Free Cash Flow | -161.63 | -457.03 | -325.71 | -225.07 | -184.13 | -157.9 | Upgrade
|
| Free Cash Flow Per Share | -7.29 | -21.48 | -17.43 | -13.13 | -11.13 | -10.22 | Upgrade
|
| Gross Margin | 95.25% | 96.54% | - | - | - | - | Upgrade
|
| Operating Margin | -41.52% | -276.39% | - | - | - | - | Upgrade
|
| Profit Margin | -39.04% | -258.64% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -21.82% | -253.72% | - | - | - | - | Upgrade
|
| EBITDA | -306.01 | -496.78 | -379.97 | -293.1 | -242.08 | -206.2 | Upgrade
|
| EBITDA Margin | -41.32% | -275.78% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 1.48 | 1.1 | 0.53 | 0.47 | 0.41 | 0.47 | Upgrade
|
| EBIT | -307.48 | -497.88 | -380.5 | -293.57 | -242.48 | -206.67 | Upgrade
|
| EBIT Margin | -41.52% | -276.39% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.